000285052 001__ 285052
000285052 005__ 20260209110547.0
000285052 0247_ $$2doi$$a10.3389/fneur.2026.1726779
000285052 0247_ $$2pmid$$apmid:41648666
000285052 0247_ $$2pmc$$apmc:PMC12867840
000285052 037__ $$aDZNE-2026-00176
000285052 041__ $$aEnglish
000285052 082__ $$a610
000285052 1001_ $$aVölker, Lotta$$b0
000285052 245__ $$aThe Berlin-Hannover ICANS severity assessment-a novel bedside test to evaluate CAR T-cell-associated neurotoxicity.
000285052 260__ $$aLausanne$$bFrontiers Research Foundation$$c2026
000285052 3367_ $$2DRIVER$$aarticle
000285052 3367_ $$2DataCite$$aOutput Types/Journal article
000285052 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770631248_24272
000285052 3367_ $$2BibTeX$$aARTICLE
000285052 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285052 3367_ $$00$$2EndNote$$aJournal Article
000285052 520__ $$aChimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory hematological malignancies but is frequently complicated by immune effector cell-associated neurotoxicity syndrome (ICANS). Early clinical recognition remains challenging, as the commonly used Immune Effector Cell-Associated Encephalopathy (ICE) score lacks sensitivity for subtle deficits.In this prospective bicentric study, 100 patients treated with CAR T-cells at Hannover Medical School and Charité - Universitätsmedizin Berlin underwent systematic neurological assessments using both ICE and the newly developed Berlin-Hannover ICANS Severity Assessment (BHISA). Examinations were performed at baseline prior to CAR T-cell infusion, on day 6-7 (±1 day) post-infusion, and during ICANS episodes. Data on the clinical course, other toxicities, comorbidities, CAR T-cell products, and ICANS treatment were collected.Thirty-seven patients (37%) developed ICANS, which was associated with preceding cytokine release syndrome and specific CAR T-cell products. While ICE scores clustered at maximum values both at baseline and follow-up, BHISA showed a broader distribution and higher sensitivity to subtle changes. Correlation analyses confirmed agreement between ICE and BHISA, but BHISA captured early cognitive decline more reliably. Receiver operating characteristic analyses demonstrated comparable diagnostic accuracy (BHISA: AUC = 0.783, ICE: AUC = 0,777), with consistently higher sensitivity of BHISA at matched specificity. (Specificity target = 0.7, BHISA sensitivity = 0.743, ICE sensitivity = 0.571; Specificity target = 0.8, BHISA sensitivity = 0.629, ICE sensitivity = 0.571).BHISA may provide a more sensitive and more differentiated screening tool for ICANS than ICE by incorporating additional cognitive and motor domains, while remaining easy to use. This may enable earlier and more nuanced detection of CAR T related neurotoxicity, potentially improving patient monitoring across a heterogeneous population.
000285052 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285052 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285052 650_7 $$2Other$$aBHISA
000285052 650_7 $$2Other$$aCAR T-cell therapy
000285052 650_7 $$2Other$$aICANS
000285052 650_7 $$2Other$$aICE
000285052 650_7 $$2Other$$ascreening tools
000285052 7001_ $$aMüller-Jensen, Leonie$$b1
000285052 7001_ $$aCarl, Sophia$$b2
000285052 7001_ $$aNay, Sandra$$b3
000285052 7001_ $$aMöllenkamp, Thiemo Malte$$b4
000285052 7001_ $$aSchultze-Florey, Christian$$b5
000285052 7001_ $$aGrote-Levi, Lea$$b6
000285052 7001_ $$aJendretzky, Konstantin F$$b7
000285052 7001_ $$aKonen, Franz Felix$$b8
000285052 7001_ $$aKönecke, Christian$$b9
000285052 7001_ $$aEder, Matthias$$b10
000285052 7001_ $$aPanagiota, Victoria$$b11
000285052 7001_ $$aHeidel, Florian H$$b12
000285052 7001_ $$aBullinger, Lars$$b13
000285052 7001_ $$aDamm, Frederik$$b14
000285052 7001_ $$aFrick, Mareike$$b15
000285052 7001_ $$aPenack, Olaf$$b16
000285052 7001_ $$aLudwig, Rebecca$$b17
000285052 7001_ $$aBuß, Eric Anil$$b18
000285052 7001_ $$aBoehmerle, Wolfgang$$b19
000285052 7001_ $$0P:(DE-2719)2811033$$aEndres, Matthias$$b20$$udzne
000285052 7001_ $$aGudi, Viktoria$$b21
000285052 7001_ $$aHuehnchen, Petra$$b22
000285052 7001_ $$aSkripuletz, Thomas$$b23
000285052 7001_ $$aMöhn, Nora$$b24
000285052 773__ $$0PERI:(DE-600)2564214-5$$a10.3389/fneur.2026.1726779$$gVol. 17, p. 1726779$$p1726779$$tFrontiers in neurology$$v17$$x1664-2295$$y2026
000285052 8564_ $$uhttps://pub.dzne.de/record/285052/files/DZNE-2026-00176.pdf$$yRestricted
000285052 8564_ $$uhttps://pub.dzne.de/record/285052/files/DZNE-2026-00176.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285052 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811033$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b20$$kDZNE
000285052 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285052 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT NEUROL : 2022$$d2025-01-07
000285052 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000285052 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000285052 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-01-11T07:34:54Z
000285052 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-01-11T07:34:54Z
000285052 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-01-11T07:34:54Z
000285052 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-01-11T07:34:54Z
000285052 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000285052 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000285052 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000285052 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000285052 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000285052 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07
000285052 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07
000285052 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lInterdisciplinary Dementia Research$$x0
000285052 980__ $$ajournal
000285052 980__ $$aEDITORS
000285052 980__ $$aVDBINPRINT
000285052 980__ $$aI:(DE-2719)1811005
000285052 980__ $$aUNRESTRICTED